| タイトル/Title | Activation and Expression of Peroxisome Proliferator-Activated Receptor Alpha Are Associated with Tumorigenesis in Colorectal Carcinoma |
|----------------|-------------------------------------------------------------------------------------------------------------------------------|
| 著者/Author(s)  | Morinishi, Tatsuya / Tokuhara, Yasunori / Ohsaki, Hiroyuki / Ibuki, Emi / Kadota, Kyuichi / Hirakawa, Eiichiro |
| 掲載誌・巻号／ページ/Citation | PPAR Research, 2019: 7486727 |
| 刊行日/Issue date | 2019-07-03 |
| 資源タイプ/Resource Type | Journal Article / 学術雑誌論文 |
| 版区分/Resource Version | publisher |
| 権利/Rights | © 2019 Tatsuya Morinishi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| DOI | 10.1155/2019/7486727 |
| JaLCDOI | |
| URL | http://www.lib.kobe-u.ac.jp/handle_kernel/90006235 |

PDF issue: 2020-05-06
Research Article

Activation and Expression of Peroxisome Proliferator-Activated Receptor Alpha Are Associated with Tumorigenesis in Colorectal Carcinoma

Tatsuya Morinishi,1 Yasunori Tokuhara,2 Hiroyuki Ohsaki,3 Emi Ibuki,4 Kyuichi Kadota,4 and Eiichiro Hirakawa1

1Laboratory of Pathology, Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Kagawa 761-0123, Japan
2Department of Medical Technology, Ehime Prefectural University of Health Sciences, Tobe, Ehime 791-201, Japan
3Laboratory of Pathology, Department of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Hyogo 654-0142, Japan
4Department of Diagnostic Pathology, University Hospital, Faculty of Medicine, Kagawa University, Miki, Kagawa 761-0793, Japan

Correspondence should be addressed to Eiichiro Hirakawa; hirakawa@chs.pref.kagawa.jp

Received 22 March 2019; Revised 23 May 2019; Accepted 23 June 2019; Published 3 July 2019

Academic Editor: Nanping Wang

Copyright © 2019 Tatsuya Morinishi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peroxisome proliferator-activated receptor alpha (PPAR-𝛼) belongs to the PPAR family and plays a critical role in inhibiting cell proliferation and tumorigenesis in various tumors. However, the role of PPAR-𝛼 in colorectal tumorigenesis is unclear. In the present study, we found that fenofibrate, a PPAR-𝛼 agonist, significantly inhibited cell proliferation and induced apoptosis in colorectal carcinoma cells. In addition, PPAR-𝛼 was expressed in the nucleus of colorectal carcinoma cells, and the expression of nuclear PPAR-𝛼 increased in colorectal carcinoma tissue compared with that of normal epithelium tissue (P<0.01). The correlation between the expression of nuclear PPAR-𝛼 and clinicopathological factors was evaluated in human colorectal carcinoma tissues, and the nuclear expression of PPAR-𝛼 was significantly higher in well-to-moderately differentiated adenocarcinoma than in mucinous adenocarcinoma (P<0.05). These findings indicate that activation of PPAR-𝛼 may be involved in anticancer effects in colorectal carcinomas, and nuclear expression of PPAR-𝛼 may be a therapeutic target for colorectal adenocarcinoma treatment.

1. Introduction

More than 1.2 million colorectal carcinomas are diagnosed every year, accounting for approximately 10% of all carcinomas worldwide [1]. There was considerable progress in the diagnosis and treatment of colorectal carcinomas in the past 10 years, but some problems in detecting and managing this disease remain. A deeper understanding of the mechanism of colorectal carcinomas at the molecular level improves early diagnosis, prognostic evaluation, and disease control [2]. Recently, the relationship of anticancer effects between colorectal carcinomas and peroxisome proliferator-activated receptors (PPARs) has been reported [3, 4].

PPARs are nuclear hormone receptors and are expressed in various species including humans [5]. PPARs regulate the transcription of several genes involved in lipid metabolism, energy utilization, and storage [6], and PPARs consist of three subtypes (PPAR-𝛼, PPAR-β/δ, and PPAR-𝛾) [7, 8]. PPAR-𝛾 can modulate the growth and differentiation of colorectal cancer cells [9], and ligand-dependent PPAR-𝛾 activation influences subcellular localization in colorectal carcinoma cell lines [10]. PPAR-𝛼 is predominantly expressed in tissues that catabolize high amounts of fatty acids such as the liver, kidney, and heart [11]. PPAR-𝛼 regulates important cellular functions, including cell proliferation, differentiation, energy metabolism, oxidative stress, inflammation, circadian
rhythms, immune response, and cell differentiation. Agonists of PPAR-α are widely used to treat hyperlipidemia because of its lipid metabolism promotion properties [12], and PPAR-α agonists also have anticancer effects [13, 14] and effects on various diseases [15–17].

Fenofibrate, a PPAR-α agonist, is used to treat different forms of hyperlipidemia and regulates transcription to control lipid transportation and metabolism [18]. Fenofibrate may have anticancer effects by directly attenuating tumor growth [19–21].

PPAR-α is localized to the nucleus in breast carcinoma by immunohistochemistry [22]. The expression of PPAR-α is significantly elevated in endometrial cancer compared with that in normal endometrium [23]. However, the relationship between the expression of PPAR-α and clinicopathologic factors in colorectal carcinoma is unclear.

In this study, we investigated the effect of PPAR-α activation by fenofibrate on cell proliferation in two colorectal carcinoma cell lines. Furthermore, we examined the localization of PPAR-α expression in colorectal carcinoma and the correlation between PPAR-α expression and clinicopathologic factors in human colorectal carcinoma tissue.

2. Materials and Methods

2.1. Cell Culture. Caco-2 cells were obtained from the American Type Culture Collection (Manassas, VA, USA), and SW620 cells were obtained from Dainippon Sumitomo Pharma (Osaka, Japan). Cells were cultured in Dulbecco’s Eagle’s medium (Wako Pure Chemical Industries, Osaka, Japan) supplemented with 10% heat-inactive fetal bovine serum (Biological Industries, Beit HaEmeq, Israel) and 1% penicillin-streptomycin (Wako Pure Chemical Industries) at 37°C in a humidified incubator with 5% CO₂ [24].

2.2. RNA Analysis. Total RNA was extracted using an RNeasy Plus Mini Kit (Qiagen, Shanghai, China) following the manufacturer’s protocol. Reverse transcription polymerase chain reaction (RT-PCR) was performed using a SuperScript VILO cDNA Synthesis Kit (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). Specific primers for PPAR-α were synthesized as follows: PPAR-α forward, 5’-CTGTCCGGATGTGTCACACAA-3’ and reverse, 5’-CCGCAAAAACCTACTGGATT-3’; GAPDH forward, 5’-CAACGACCACTTGTCGACCG-3’ and reverse, 5’-TCTTCAGGGGTCTCATG-3’. The samples were initially denatured at 95°C for 10 min prior to the thermal cycle (PC-707, ASTEC, Fukuoka, Japan). The thermal cycler for PCR was as follows: 95°C for the 30 s, 63°C for 30 s, and 72°C for 1 min for 35 cycles. The PCR products were separated on a 2% agarose gel and visualized under LED 100 illumination (AMZ System Science, Osaka, Japan).

2.3. Protein Extraction and Western Blotting. Western blotting was performed as described previously [24]. Cells were seeded on 60-mm dishes and incubated at 37°C until confluent. Cells were washed with PBS, dissolved by lysis buffer (50 mM Tris-HCl, 1% Triton X-100, 100 mM NaCl, 10 mM MgCl₂, 1 mM EDTA), and incubated on ice for 20 min. Lysates were centrifuged at 20,630 × g for 20 min at 4°C. The supernatants were collected, and 2× sample buffer (Nacalai Tesque, Kyoto, Japan) was added and heated for 3 min to denature the proteins. Western blotting was performed after protein separation by electrophoresis on an SDS polyacrylamide gel (Oriental Instruments, Kanagawa, Japan). Proteins separated by SDS-PAGE were transferred to a polyvinylidene fluoride (PVDF) membrane (Merck KGaA, Darmstadt, Germany) by an electrophoretic transfer system. The PVDF membrane was blocked at room temperature using 2% skimmed milk powder and then incubated with mouse anti-PPAR-α monoclonal antibody (1:500, Santa Cruz Biotechnology, San Francisco, CA, USA, catalog no. sc-398394), rabbit anti-β-actin monoclonal antibody (1:5,000, Cell Signaling Technology, Danvers, MA, USA, catalog no. 4970S), or anti-Lamin B2 antibody (1:5,000, Novus Biologicals, Littleton, CO, USA, catalog no. NB2-43834). The membrane was washed and incubated with horseradish peroxidase-conjugated anti-rabbit antibody (1:5,000, Cell Signaling Technology, Danvers, MA, USA, catalog no. 4074S) or horseradish peroxidase-conjugated anti-mouse antibody (1:5,000, Cell Signaling Technology, Danvers, MA, USA, catalog no. 4076S) at room temperature for 1 h. Immunoreactivity was detected with an enhanced chemiluminescence kit Chemi-Lumi One L (Nacalai Tesque). Protein levels were quantified by ImageJ (version 1.52a) [25], and β-actin was used as an internal control.

2.4. Isolation of Cytoplasm and Nucleus. Cytoplasmic and nuclear proteins were isolated using a Cytoplasmic & Nuclear Protein Extraction Kit (101Bio, Palo Alto, CA, USA) according to the manufacturer’s instructions. Fractions were immunoblotted with appropriate antibodies. Lamin B2 was used as a nuclear marker.

2.5. Cell Proliferation Analysis. Cell proliferation was measured by an MTT Cell Proliferation Assay Kit (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer’s instructions. In brief, cells were seeded onto 96-well microplates (Thermo Fisher Scientific, Waltham, MA, USA) at a density of 8 × 10⁴ cells/mL in a volume of 100 μL culture media for 24 h. Cells were then incubated in culture medium with fenofibrate, or fenofibrate and GW6471 for 48 h. MTT reagent was added in each well and incubated at 37°C for 3 h. Afterwards, Crystal Dissolving Solution (Cayman Chemical) was added into each well and further incubated at 37°C for 6 h. The optical density values (OD value) were measured at 570 nm using a model 680 Microplate Reader (Bio-Rad Laboratories, Hercules, CA, USA).

2.6. Hoechst Staining. Apoptosis was detected by Hoechst staining for analysis of chromatin condensation or nuclear fragmentation. In brief, cells were seeded onto 60-mm dishes at a density of 1 × 10⁶ cells/mL in a volume of 4 mL culture media for 24 h. Cells were then incubated in culture medium with fenofibrate, or fenofibrate and GW6471 for 48 h. The cells were harvested and stained by 1 mg/mL bisbenzimide H33258 (Sigma, St. Louis, MO, USA). The nucleus of the stained cells was observed in several fields by a fluorescence microscope (Nikon Eclipse E600, Nikon Instruments, Melville, NY, USA), and the ratio of apoptotic cells was determined.
2.7. Immunocytochemistry. The cells were seeded on Nunc Lab-Tek chamber slides (Thermo Fisher Scientific) and incubated at 37°C until confluent. Cells were subsequently washed twice with PBS and fixed with 3.7% formalin at room temperature for 15 min. The cells were permeabilized with 0.25% triton in PBS for 10 min and blocked with 2% bovine serum albumin (Wako Pure Chemical Industries) in PBS for 1 h. Cells were incubated at room temperature for 2 h with HRP-labeled anti-PPAR-α antibody (1:200, Santa Cruz Biotechnology, catalog no. sc-398394). The cells were rinsed three times with PBS and then stained with 3,3'-diaminobenzidine tetrahydrochloride (DAB) using a DAB substrate kit (Nichirei Biosciences, Tokyo, Japan). The cells were counterstained with Meyer's hematoxylin, dehydrated, cleared with 99% xylene for 15 min, and mounted in malinol (Muto Pure Chemicals, Tokyo, Japan). The expression of PPAR-α in cells was observed at 200x magnification using a light microscope (BX53; Olympus Corporation, Tokyo, Japan), and images were captured with a microscopic camera (DP20-5; Olympus Corporation).

2.8. Subjects. Tissues were obtained from 64 cases diagnosed as colorectal carcinoma and surgically resected between April 2012 and March 2014 at Kagawa University Hospital (Kagawa, Japan). Clinicopathological factors were classified according to histological differentiation degree, lymphatic invasion, venous invasion, lymph node metastasis, depth of invasion, and stage according to the Japanese Classification of Colorectal Carcinoma (8th Edition). All subjects provided written informed consent. The study was conducted with the approval of the Institutional Research Ethics Committee of Kagawa Prefectural University of Health Sciences (Kagawa, Japan).

2.9. Immunohistochemistry. Immunohistochemistry was performed as described previously [26]. The tissue sections were incubated at room temperature for 2 h with the following primary antibody: HRP-labeled anti-PPAR-α antibody (1:200, Santa Cruz Biotechnology, catalog no. sc-398394). Slides were rinsed three times with PBS and then stained with DAB using the DAB substrate kit (Nichirei Biosciences). Sections were counterstained with Meyer's hematoxylin, dehydrated, cleared with 99% xylene, and then mounted in malinol. The expression of PPAR-α in cells was observed at 200x magnification using a light microscope (BX53; Olympus Corporation, Tokyo, Japan), and images were captured with a microscopic camera (DP20-5; Olympus Corporation).

2.10. Statistical Analysis. Protein expression by western blotting, the survival rate of colorectal carcinoma cell by MTT assay, and the proportion of cells producing apoptosis by Hoechst stain were analyzed using a paired Student's t-test. The correlation between immunohistochemical staining and clinicopathological factors was examined using the χ² test. P<0.05 was considered significant. All statistical analyses were performed using SPSS 24.0 software (IBM SPSS, Armonk, NY, USA).

3. Results

3.1. Expression of PPAR-α in Colorectal Carcinoma Cell Lines. Expression of PPAR-α mRNA and PPAR-α protein levels in colorectal carcinoma cell lines (Caco-2 and SW620 cells) was examined. First, expression of PPAR-α mRNA was examined by RT-PCR in a colorectal carcinoma cell line. We confirmed the expression of PPAR-α RNA in Caco-2 and SW620 cells (Figure 1(a)). In addition, expression of PPAR-α protein was examined by western blotting in the colorectal carcinoma cell lines, and there was no difference in the amount of PPAR-α protein in Caco-2 and SW620 cells (Figures 1(b) and 1(c)).

3.2. Localization of PPAR-α in Caco-2 and SW620 Cells. Immunocytochemical analysis was performed to determine the subcellular localization of PPAR-α in Caco-2 and SW620 cells. PPAR-α was mainly localized in the nucleus of the colorectal carcinoma cell lines (Figures 2(a) and 2(b)). Next, Caco-2 and SW620 cells were divided into cell fractions (nucleus and cytoplasm), and the expression of PPAR-α was confirmed by comparing the amount of PPAR-α protein by western blotting. PPAR-α was expressed in the nucleus and was not expressed in the cytoplasm (Figure 2(c)).

3.3. Fenofibrate Inhibits the Viability of Colorectal Carcinoma Cells by MTT Assay. The effect of different concentrations of fenofibrate on the viability of colorectal carcinoma cells was evaluated using an MTT assay. Colorectal carcinoma cells were treated with fenofibrate (200 μM for Caco-2 cells and 100 μM for SW620 cells; DMSO was used as a control for each group) and incubated for 48 h (Figure 3). Fenofibrate significantly decreased Caco-2 and SW620 cell viability (P<0.01 and P<0.01, respectively). GW6471 (3 μM), an antagonist of PPAR-α, was added to fenofibrate (200 μM for Caco-2 cells and 100 μM for SW620 cells), which significantly suppressed the antiproliferative effect of PPAR-α by fenofibrate in Caco-2 and SW620 cells (P<0.05 and P<0.01, respectively) (Figure 3).

3.4. Fenofibrate Increases Apoptotic Cells. A Hoechst stain was used to examine apoptotic Caco-2 and SW620 cells after treatment with fenofibrate (100 μM for Caco-2 and SW620 cells; DMSO was used as a control for each group). The number of apoptotic cells was significantly increased by addition of fenofibrate to Caco-2 and SW620 cells (P<0.01 and P<0.01, respectively) (Figure 4). GW6471 (3 μM) was added to fenofibrate (100 μM), which significantly suppressed the increase of Caco-2 and SW620 apoptotic cells (P<0.01 and P<0.01, respectively) (Figure 4).

3.5. Relationship between PPAR-α Expression and Clinicopathological Factors by Tissue Immunohistochemistry. Paraffin-embedded colorectal carcinoma tissue blocks
Figure 1: PPAR-α mRNA and protein are expressed in colorectal carcinoma cells. (a) RT-PCR analysis of PPAR-α in Caco-2 and SW620 cells. (b) PPAR-α protein was assayed by western blot in Caco-2 and SW620 cells. (c) PPAR-α protein levels were calculated and compared with those of Caco-2 and SW620 cells. Error bars indicate standard deviation.

Figure 2: Localization of PPAR-α in Caco-2 and SW620 cells. (a, b) Immunocytochemical staining of PPAR-α in Caco-2 and SW620 cells. (c) PPAR-α was expressed in the nucleus of Caco-2 and SW620 cells.
were provided by Kagawa University Hospital (Kagawa, Japan). There were 64 patients (39 males and 25 females) with a mean age of 68.6 ± 12.6. Fifty-two cases were differentiated carcinoma types, and 12 cases were mucinous adenocarcinoma. Forty-eight cases were positive and 16 cases were negative for lymphatic invasion; 48 cases were positive and 16 cases were negative for venous invasion. Lymph node metastasis was observed in 21 cases. For the depth of invasion, 1 case was T0, 5 cases were T1, 3 cases were T2, 34 cases were T3, and 21 cases were T4. For the progress (stage) classification, 1 case was stage 0, 7 cases were stage I, 34 cases were stage II, 21 cases were stage III, and 1 case was stage IV. PPAR-\(\alpha\) expression was mainly localized in the nucleus in well-to-moderately differentiated cancer cells (Figure 5(a)), and almost no expression was observed in normal epithelium tissue (Figure 5(b)). PPAR-\(\alpha\) expression increased in colorectal carcinoma tissue and decreased in normal epithelium tissue (P<0.01) (Table 1). As shown in Table 2, PPAR-\(\alpha\) expression was not related to sex, age, lymphatic invasion, venous invasion, lymph node metastasis, depth of invasion, and stage. However, the expression of PPAR-\(\alpha\) declined in mucinous adenocarcinoma (Figure 5(c)), and PPAR-\(\alpha\) expression in well-to-moderately differentiated adenocarcinoma was significantly higher than in mucinous adenocarcinoma (P<0.05) (Table 2).

4. Discussion

We examined the activity of PPAR-\(\alpha\) by fenofibrate in colorectal carcinoma cell lines. PPAR-\(\alpha\) was involved in cell survival because fenofibrate decreased cancer cell proliferation and induced apoptosis, which was suppressed by addition of GW6471 in colorectal carcinoma cells (Figures 3 and 4(g)). PPAR-\(\alpha\)-dependent mechanisms have been used to explain the anticancer effects of fenofibrate in breast cancer [27], pancreatic cancer [28], ovarian cancer [29], endometrial cancer [30], neuroblastoma cells [31], proximal tubular cells [32], lymphoma, and multiple myeloma [33], but little has been reported about PPAR-\(\alpha\) in colorectal carcinoma. Fenofibrate decreased cell proliferation and increased apoptosis of colorectal carcinoma cells, which expressed PPAR-\(\alpha\) (Figures 2(a) and 2(b)). These findings indicated that PPAR-\(\alpha\) has possible anticancer effects in colorectal carcinoma.

PPAR-\(\alpha\) was expressed in the nucleus of carcinoma cells (Figures 2(a), 2(b), and 2(c)). PPAR-\(\gamma\) is expressed in the nucleus of cancer cells in breast cancer [22], but PPAR-\(\gamma\) is expressed in the cytoplasm and nucleus in renal cell carcinoma [34]. However, the localization of PPAR-\(\alpha\) in colorectal carcinoma tissue has not been reported. The expression of nuclear PPAR-\(\alpha\) is significantly increased in endometrial cancer compared with that of normal endometrium [23]. Additionally, neoplastic cells have strong PPAR-\(\alpha\) expression and activity, which increase metabolic rates in cancer cells [23]. We found that PPAR-\(\alpha\) was expressed in the nucleus in large intestine carcinogenetic tissue.

We found that PPAR-\(\alpha\) expression in normal epithelium tissue was lower than in well-to-moderately differentiated adenocarcinoma (Figures 5(a) and 5(b)) (Table 1). Moreover, we examined the correlation between clinicopathological factors and PPAR-\(\alpha\) expression and localization in colorectal carcinoma. PPAR-\(\alpha\) expression in well-to-moderately differentiated adenocarcinoma was significantly higher than in mucinous adenocarcinoma (Figures 5(a) and 5(c)) (Table 2). Colorectal mucinous adenocarcinoma accounts for 5-20% of colorectal carcinoma and is characterized by viscous liquid (>50% of the tumor region) in the extracellular space [35, 36]. There are no reports of PPARs in mucinous adenocarcinoma. The cultured cells in this study were established from primary colorectal carcinoma patients (Caco-2) and metastasized lymph nodes (SW620), and these cells do not produce mucus. PPAR-\(\alpha\) was expressed in the nucleus of colorectal carcinoma cells, which do not produce mucus in vivo and in vitro (Figures 2(a), 2(b), and 5(a)). Compared with well-to-moderately differentiated adenocarcinoma, mucinous adenocarcinoma has a larger tumor size and higher pathological stage, and patients with mucinous adenocarcinoma have an increased risk of metastasis and worse prognosis [37].

PPAR-\(\alpha\) was localized in the nucleus of colorectal carcinoma (Figures 5(a) and 5(b)), and fenofibrate induced apoptosis and suppressed tumor proliferation by activating PPAR-\(\alpha\) in cultured cells (Figures 3 and 4). These findings suggest that activation of PPAR-\(\alpha\) by fenofibrate may inhibit

![Figure 3: PPAR-\(\alpha\) activation affects cell proliferation. Human colorectal carcinoma cells (Caco-2 and SW620) were treated with fenofibrate (200 \(\mu\)M for Caco-2 cells and 100 \(\mu\)M for SW620 cells) and 3 \(\mu\)M of GW6471 for 48 h, and cell proliferation was determined by an MTT assay. Error bars indicate standard deviation.](image)
Table 2: The relationship of PPAR-α expression to clinicopathologic parameters of colorectal carcinoma (n=64).

| Parameters                        | Number of cases | PPAR-α | P-value |
|-----------------------------------|-----------------|--------|---------|
|                                   | (-)             | (+)    |         |
| Sex                               |                 |        |         |
| Male                              | 39              | 8      | 31      | 0.985   |
| Female                            | 25              | 6      | 19      |         |
| Age                               |                 |        |         |
| ≤65                               | 31              | 8      | 23      | 0.664   |
| >65                               | 33              | 6      | 27      |         |
| Histological type                 |                 |        |         |
| Well-to-moderately differentiated | 52              | 8      | 44      | 0.026   |
| Mucinous                          | 12              | 6      | 6       |         |
| Lymphatic invasion                |                 |        |         |
| Positive                          | 48              | 11     | 37      | 1.000   |
| Negative                          | 16              | 3      | 13      |         |
| Venous invasion                   |                 |        |         |
| Positive                          | 48              | 10     | 38      | 1.000   |
| Negative                          | 16              | 4      | 12      |         |
| Lymph node metastasis             |                 |        |         |
| Positive                          | 21              | 5      | 16      | 1.000   |
| Negative                          | 43              | 9      | 34      |         |
| Depth of invasion                 |                 |        |         |
| T0                                | 1               | 0      | 1       | 1.000   |
| T1                                | 5               | 0      | 5       |         |
| T2                                | 3               | 1      | 2       | 0.734   |
| T3                                | 34              | 8      | 26      |         |
| T4                                | 21              | 5      | 16      |         |
| Stage                             |                 |        |         |
| 0                                 | 1               | 0      | 1       | 1.000   |
| I                                 | 7               | 1      | 6       |         |
| II                                | 34              | 8      | 26      | 0.970   |
| IIIa                              | 17              | 4      | 13      |         |
| IIIb                              | 4               | 1      | 3       |         |
| IV                                | 1               | 0      | 1       |         |

Figure 4: Continued.
Figure 4: PPAR-α activation affects apoptosis. (a) Control in Caco-2 cells (200×). (b) 100 μM of fenofibrate in Caco-2 cells (200×). (c) 100 μM of fenofibrate and 3 μM of GW6471 in Caco-2 cells (200×). (d) Control in SW620 cells (200×). (e) 100 μM of fenofibrate in SW620 cells (200×). (f) 100 μM of fenofibrate and 3 μM of GW6471 in SW620 cells (200×). (g) Human colorectal carcinoma cells (Caco-2 and SW620) were treated with 100 μM of fenofibrate, and 100 μM of fenofibrate and 3 μM of GW6471 for 48 h; apoptosis was determined by a Hoechst stain. Error bars indicate standard deviation.

Figure 5: Expression of PPAR-α in different histological types. (a) Positive PPAR-α expression in well-to-moderately differentiated adenocarcinoma (200×). (b) Negative PPAR-α expression in normal epithelium tissue (200×). (c) Negative PPAR-α expression in mucinous adenocarcinoma (200×).
colorectal carcinoma cell survival. PPARs are nuclear receptors that are activated in the nucleus to regulate various transcription factors. PPAR-γ ligands were previously shown to significantly induce apoptosis in colon cancer cells by suppressing the activity of NF-κB, which is a transcription factor of Bcl-2, and inhibiting the expression of antiapoptotic Bcl-2 proteins [38–40]. NF-κB and Bcl-2 have been suggested to play important roles in the activation of PPAR-γ and apoptosis in human colon cancer cells [39]. Previous studies reported the downregulation of NF-κB signaling in fenofibrate-related apoptosis [27, 41, 42]. A PPAR-α ligand was shown to induce apoptosis in breast cancer cells, which may have been due to the inhibition of NF-κB [27], and the activation of PPAR-α also decreased the growth rate of breast cancer cells by reducing the levels of various cell cycle-regulating cyclins [43]. Therefore, Bcl-2 and its transcription factor, NF-κB, may suppress tumor proliferation via the activation of PPAR-α in colorectal carcinoma. However, the mechanisms underlying the relationship between tumor cell proliferation, including apoptosis, and the transcriptional activity of PPAR-α remain unclear. Further studies are needed to clarify the mechanisms by which PPAR-α regulates the induction of apoptosis in colorectal carcinoma.

In summary, we found that PPAR-α activation by fenofibrate reduced the survival rate of colorectal carcinoma cells. Moreover, PPAR-α expression increased in colorectal carcinoma compared with that in normal epithelium tissue. PPAR-α activation by agonists may have an anticancer effect on colorectal adenocarcinoma, and nuclear expression of PPAR-α may be a therapeutic target for colorectal adenocarcinoma.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication of this paper.

References
[1] L. Sabatino, M. Pancione, C. Votino et al., “Emerging role of the β-catenin-PPARγ axis in the pathogenesis of colorectal cancer,” World Journal of Gastroenterology, vol. 20, no. 23, pp. 7137–7151, 2014.
[2] M. R. Milone, B. Pucci, T. Colangelo et al., “Proteomic characterization of peroxisome proliferator-activated receptor-γ (PPARγ) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype,” Molecular Oncology, vol. 10, no. 8, pp. 1344–1362, 2016.
[3] S. Theocharis, C. Giaginis, A. Parasi et al., “Expression of peroxisome proliferator-activated receptor-γ in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients’ survival,” Digestive Diseases and Sciences, vol. 52, no. 9, pp. 2305–2311, 2007.
[4] T. Tsukahara, H. Haniu, and Y. Matsuda, “PTB-associated splicing factor (PSF) is a PPARγ-binding protein and growth regulator of colon cancer cells,” PLoS ONE, vol. 8, no. 3, Article ID e58749, 2013.
[5] I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
[6] A. Pozzi, M. R. Ibanez, A. E. Gatica et al., “Peroxisomal proliferator-activated receptor-α-dependent inhibition of endothelial cell proliferation and tumorigenesis,” The Journal of Biological Chemistry, vol. 282, no. 24, pp. 17685–17695, 2007.
[7] Y. Yokoyama, B. Xin, T. Shigeto et al., “Clofibrate acid, a peroxisome proliferator-activated receptor α ligand, inhibits growth of human ovarian cancer,” Molecular Cancer Therapeutics, vol. 6, no. 4, pp. 1379–1386, 2007.
[8] S. Ramanan, M. Kooshki, W. Zhao, F.-C. Hsu, and M. E. Robbins, “PPARα ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-κB and AP-1 pathways,” Free Radical Biology & Medicine, vol. 45, no. 12, pp. 1695–1704, 2008.
[9] P. Sarraf, E. Mueller, D. Jones et al., “Differentiation and reversal of malignant changes in colon cancer through PPARgamma,” Nature Medicine, vol. 4, pp. 1046–1052, 1998.
[10] A. Panza, V. Pazienza, M. Ripoli et al., “Interplay between SOX9, beta-catenin and PPARgamma activation in colorectal cancer,” Biochimica et Biophysica Acta, vol. 1833, pp. 1853–1865, 2013.
[11] S. A. Kliewer, B. M. Forman, B. Blumberg et al., “Differential expression and activation of a family of murine peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7355–7359, 1994.
[12] A. Sahebkar and G. F. Watts, “Challenges in the treatment of hypertriglyceridemia: glass half empty or half full?” Expert Review of Clinical Pharmacology, vol. 8, no. 4, pp. 363–366, 2015.
[13] T. Pang, A. Kaufman, J. Choi et al., “Peroxisome proliferator-activated receptor-α staining is associated with worse outcome in colorectal liver metastases,” Molecular and Clinical Oncology, vol. 3, no. 2, pp. 308–316, 2015.
[14] A. Papi, T. Guarnieri, G. Storci et al., “Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells,” Cell Death & Differentiation, vol. 19, no. 7, pp. 1208–1219, 2012.
[15] R. Bordet, T. Ouk, O. Petrault et al., “PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases,” Biochemical Society Transactions, vol. 34, no. 6, pp. 1341–1346, 2006.
[16] A. Y. Y. Cheng and L. A. Leiter, “PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease,” Diabetes, Obesity and Metabolism, vol. 10, no. 9, pp. 691–698, 2008.
[17] J. K. Barbiero, R. Santiago, F. S. Tonin et al., “PPAR-alpha agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson’s disease,” Progress in Neuro-PsychoPharmacology & Biological Psychiatry, vol. 33, pp. 35–44, 2014.
[18] D. Yamasaki, N. Kawabe, H. Nakamura et al., “Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms,” European Journal of Cell Biology, vol. 90, no. 8, pp. 657–664, 2011.
[19] M. Maggiora, M. Oraldi, G. Muzio, and R. A. Canuto, “Involvement of PPARα and PPARγ in apoptosis and proliferation of human hepatocarcinoma HepG2 cells,” Cell Biochemistry & Function, vol. 28, no. 7, pp. 571–577, 2010.
[20] J. Shoda, Y. Inada, A. Tsuji et al., “Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARα-mediated redistribution of ABCB4,” *Journal of Lipid Research*, vol. 45, no. 10, pp. 1813–1823, 2004.

[21] G. Martinasso, M. Oraldi, A. Trombetta et al., “Involvement of PPARs in cell proliferation and apoptosis in human colon cancer specimens and in normal and cancer cell lines,” *PPAR Research*, Article ID 93416, 2007.

[22] N. Ditsch, D. Mayr, M. Lenhard et al., “Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinoma,” *Oncology Letters*, vol. 4, no. 4, pp. 665–671, 2012.

[23] P. Knapp, A. Chabowski, A. Blachnio-Zabielska, K. Jarząbek, and S. Wolczyński, “Altered peroxisome-proliferator activated receptors expression in human endometrial cancer,” *PPAR Research*, vol. 2012, Article ID 471524, 5 pages, 2012.

[24] X. Zhang, D. Liang, Z.-H. Chi et al., “Effect of zinc on high glucose-induced epithelial-to-mesenchymal transition in renal tubular epithelial cells,” *International Journal of Molecular Medicine*, vol. 35, no. 6, pp. 1747–1754, 2015.

[25] C. A. Schneider, W. S. Rasband, and K. W. Eliceiri, “NIH Image to Image: 25 years of image analysis,” *Nature Methods*, vol. 9, no. 7, pp. 671–675, 2012.

[26] Y. Tokuhara, T. Morinishi, T. Matsunaga et al., “Claudin-1, but not claudin-4, exhibits differential expression patterns between well- to moderately-differentiated and poorly-differentiated gastric adenocarcinoma,” *Oncology Letters*, vol. 10, no. 1, pp. 93–98, 2015.

[27] T. Li, Q. Zhang, J. Zhang et al., “Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway,” *BMC Cancer*, vol. 14, article 96, 2014.

[28] D. Hu, C. Su, M. Jiang et al., “Fenofibrate inhibited pancreatic cancer cells proliferation via activation of p53 mediated by upregulation of LncRNA MEG3,” *Biochemical and Biophysical Research Communications*, vol. 471, no. 2, pp. 290–295, 2016.

[29] H. Wang, C. H. He, L. P. Bai, Q. M. Guo, and A. Zheng, “Effects of fenofibrate on the growth and migration of ovarian cancer cells in vitro,” Journal of Sichuan University. Medical Science Edition, vol. 45, pp. 789–792, 2014.

[30] S. A. Saidi, C. M. Holland, D. S. Charnock-Jones, and S. K. Smith, “In vitro and in vivo effects of the PPARα agonists fenofibrate and retinoic acid in endometrial cancer,” *Molecular Cancer*, vol. 5, p. 13, 2006.

[31] C. Su, A. Shi, G. Cao et al., “Fenofibrate suppressed proliferation and migration of human neuroblastoma cells via oxidative stress dependent of TXNIP upregulation,” *Biochemical and Biophysical Research Communications*, vol. 460, no. 4, pp. 983–988, 2015.

[32] N. Zuo, X. Zheng, H. Liu, and X. Ma, “Fenofibrate, a PPARα agonist, protect proximal tubular cells from albumin-bound fatty acids induced apoptosis via the activation of NF-κB,” *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 9, pp. 10653–10661, 2015.

[33] L. C. Schmeel, F. C. Schmeel, and I. G. H. Schmidt-Wolf, “In vitro apoptosis induction by fenofibrate in lymphoma and multiple myeloma,” *Anticancer Research*, vol. 37, pp. 3513–3520, 2017.

[34] C. Zhu, J. Wei, X. Tian, Y. Li, and X. Li, “Prognostic role of PPAR-γ and PTEN in the renal cell carcinoma,” *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 10, pp. 12668–12677, 2015.

[35] G. Li, S. Yang, P. Shen et al., “SCF/c-KIT signaling promotes mucous secretion of colonic goblet cells and development of mucinous colorectal adenocarcinoma,” *American Journal of Cancer Research*, vol. 8, pp. 1064–1073, 2018.

[36] H. Debuin and W. Ceelen, “Mucinous differentiation in colorectal cancer: molecular, histological and clinical aspects,” *Acta Chirurgica Belgica*, vol. 113, no. 6, pp. 385–390, 2016.

[37] J. S. Park, J. W. Huh, Y. A. Park et al., “Prognostic comparison between mucinous and nonmucinous adenocarcinoma in colorectal cancer,” *Medicine*, vol. 94, no. 15, p. e658, 2015.

[38] S. Grimm, M. K. A. Bauer, P. A. Baueuerle, and K. Schulze-Osthoff, “Bcl-2 down-regulates the activity of transcription factor NF-κB induced upon apoptosis,” *The Journal of Cell Biology*, vol. 134, no. 1, pp. 13–23, 1996.

[39] G. G. Chen, J. F. Lee, S. H. Wang, U. P. Chan, P. C. Ip, and W. Y. Lau, “Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-κB in human colon cancer,” *Life Sciences*, vol. 70, no. 22, pp. 2631–2646, 2002.

[40] S. D. Catz and J. L. Johnson, “Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer,” *Oncogene*, vol. 20, no. 50, pp. 7342–7351, 2001.

[41] Z. Zak, P. Gelebart, and R. Lai, “Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFα/NF-κB signaling axis,” *Leukemia*, vol. 24, no. 8, pp. 1476–1486, 2010.

[42] H. Liang, P. Kowalczyk, J. J. Junco et al., “Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors,” *Molecular Carcinogenesis*, vol. 53, no. 9, pp. 753–763, 2014.

[43] K. Chandran, S. Goswami, and N. Sharma-Walia, “Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer,” *Oncotarget*, vol. 7, no. 13, pp. 15577–15599, 2016.
